Terrie Curran is the former President, Global Inflammation and Immunology (I&I) Franchise and member of the Executive Committee at Celgene Corporation and has more than 20 years of experience in the biopharmaceutical industry. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA®.
Prior to joining Celgene, she served as Senior Vice President and General Manager, Global Women’s Health at Merck & Co.
She currently serves on the Board of Arcutis Biotherapeutics (Nasdaq:ARQT), Myovant Sciences (NYSE:MYOV), and previously served on the board of H. Lundbeck A/S.
Ms. Curran holds graduate and bachelor’s degrees from the University of Technology Sydney.